Israel - English - Ministry of Health

organon pharma israel ltd., israel - ezetimibe - tablets - ezetimibe 10 mg - ezetimibe - ezetimibe - primary hypercholesterolemia: ezetrol administered with an hmg-coa reductase inhibitor (statin) or alone are indicated as adjunctive therapy to diet for use in patients with primary (heterozygous familial and non-familial) hypercholesterolemia. homozygous familial hypercholesterolemia (hofh): ezetrol administered with a statin are indicated for use in patients with hofh.patients may also receive adjunctive treatments (e.g. ldl apheresis).homozygous sitosterolemia (phytosterolemia): ezetrol are indicated for use in patients with homozygous familial sitosterolemia.

Israel - English - Ministry of Health

organon pharma israel ltd., israel - desogestrel - film coated tablets - desogestrel 0.075 mg - desogestrel - desogestrel - contraceptive.

Israel - English - Ministry of Health

organon pharma israel ltd., israel - ethinylestradiol; etonogestrel - vaginal ring - ethinylestradiol 2.7 mg; etonogestrel 11.7 mg - ethinylestradiol - ethinylestradiol - contraception. the safety and efficacy has been established in women aged 18 to 40 years.

Israel - English - Ministry of Health

organon pharma israel ltd., israel - etoricoxib - film coated tablets - etoricoxib 60 mg - etoricoxib - etoricoxib - arcoxia 60 mg tablets are indicated for the symptomatic relief of osteoarthritis (oa), rheumatoid arthritis (ra) and ankylosing spondylitis.

Israel - English - Ministry of Health

organon pharma israel ltd., israel - etoricoxib - film coated tablets - etoricoxib 90 mg - etoricoxib - etoricoxib - arcoxia 90 mg tablets are indicated for the symptomatic relief of rheumatoid arthritis (ra) and ankylosing spondylitis.for the short-term treatment of moderate pain associated with dental surgery.

Israel - English - Ministry of Health

organon pharma israel ltd., israel - etoricoxib - film coated tablets - etoricoxib 120 mg - etoricoxib - etoricoxib - arcoxia 120 mg tablets are indicated for the symptomatic relief of the pain and signs of inflammation associated with acute gouty arthritis.

Israel - English - Ministry of Health

organon pharma israel ltd., israel - etoricoxib - film coated tablets - etoricoxib 30 mg - etoricoxib - etoricoxib - arcoxia tablets are indicated for the symptomatic relief of osteoarthritis (oa).

Singapore - English - HSA (Health Sciences Authority)

organon singapore pte. ltd. - (core) etonogestrel - implant - 68mg - (core) etonogestrel 68mg

Australia - English - Department of Health (Therapeutic Goods Administration)

organon pharma pty ltd - tibolone, quantity: 2.5 mg - tablet, uncoated - excipient ingredients: magnesium stearate; ascorbyl palmitate; potato starch; lactose monohydrate - short-term treatment of symptoms resulting from the natural or surgical menopause in post menopausal women. second line therapy for the prevention of bone mineral density loss in postmenopausal women at high risk of future osteoporotic fractures who are intolerant of, or contraindicated for, other medicinal products approved for the prevention of bone mineral density loss. after careful selection of users, xyvion should be prescribed for the shortest duration consistent with treatment goals. review the need for continuation of treatment after 6 months, taking into account the risk-benefit ratio for the individual user at the moment (including cardiovascular disease and breast cancer, refer clinical trials and precautions). xyvion should only be continued for as long as the benefit outweighs the risks.

Australia - English - Department of Health (Therapeutic Goods Administration)

organon pharma pty ltd - tibolone, quantity: 2.5 mg - tablet, uncoated - excipient ingredients: magnesium stearate; potato starch; lactose monohydrate; ascorbyl palmitate - short-term treatment of symptoms resulting from the natural or surgical menopause in post menopausal women. second line therapy for the prevention of bone mineral density loss in postmenopausal women at high risk of future osteoporotic fractures who are intolerant of, or contraindicated for, other medicinal products approved for the prevention of bone mineral density loss. after careful selection of users, livial should be prescribed for the shortest duration consistent with treatment goals. review the need for continuation of treatment after 6 months, taking into account the risk-benefit ratio for the individual user at the moment (including cardiovascular disease and breast cancer, refer clinical trials and precautions). livial should only be continued for as long as the benefit outweighs the risks.